Education
About Us
Working with TipRanks
Follow Us
D.Western Therapeutics Institute, Inc. (DE:6DW)
FRANKFURT:6DW
Total Valuation
D.Western Therapeutics Institute has a market cap or net worth of €31.23M. The enterprise value is €3.32B.
Market Cap€31.23M
Enterprise Value€3.32B
Share Statistics
D.Western Therapeutics Institute has 54,251,713 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding54,251,713
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
D.Western Therapeutics Institute’s return on equity (ROE) is -0.44 and return on invested capital (ROIC) is -30.02%.
Return on Equity (ROE)-0.44
Return on Assets (ROA)-0.29
Return on Invested Capital (ROIC)-30.02%
Return on Capital Employed (ROCE)-0.32
Revenue Per Employee18.46M
Profits Per Employee-30.10M
Employee Count21
Asset Turnover0.18
Inventory Turnover0.99
Valuation Ratios
The current PE Ratio of D.Western Therapeutics Institute is ―. D.Western Therapeutics Institute’s PEG ratio is 0.11.
PE Ratio―
PS Ratio11.87
PB Ratio3.21
Price to Fair Value3.21
Price to FCF-9.27
Price to Operating Cash Flow0.00
PEG Ratio0.11
Income Statement
In the last 12 months, D.Western Therapeutics Institute had revenue of 387.62M and earned -632.09M in profits. Earnings per share was -13.19.
Revenue387.62M
Gross Profit301.24M
Operating Income-619.87M
Pretax Income-630.49M
Net Income-632.09M
EBITDA-572.35M
Earnings Per Share (EPS)-13.19
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
D.Western Therapeutics Institute pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.85
52-Week Price Change-29.37%
50-Day Moving Average0.50
200-Day Moving Average0.56
Relative Strength Index (RSI)49.05
Average Volume (3m)0.00
Important Dates
D.Western Therapeutics Institute upcoming earnings date is May 7, 2026, TBA (Not Confirmed).
Last Earnings DateFeb 13, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
D.Western Therapeutics Institute as a current ratio of 9.91, with Debt / Equity ratio of 42.16%
Current Ratio9.91
Quick Ratio9.48
Debt to Market Cap0.13
Net Debt to EBITDA1.93
Interest Coverage Ratio-70.32
Taxes
In the past 12 months, D.Western Therapeutics Institute has paid 1.59M in taxes.
Income Tax1.59M
Effective Tax Rate>-0.01
Enterprise Valuation
D.Western Therapeutics Institute EV to EBITDA ratio is -6.11, with an EV/FCF ratio of -7.04.
EV to Sales9.02
EV to EBITDA-6.11
EV to Free Cash Flow-7.04
EV to Operating Cash Flow-7.08
Balance Sheet
D.Western Therapeutics Institute has €1.05B in cash and marketable securities with €517.95M in debt, giving a net cash position of €529.91M billion.
Cash & Marketable Securities€1.05B
Total Debt€517.95M
Net Cash€529.91M
Net Cash Per Share€9.77
Tangible Book Value Per Share€29.95
Margins
Gross margin is 80.64%, with operating margin of -159.92%, and net profit margin of -163.07%.
Gross Margin80.64%
Operating Margin-159.92%
Pretax Margin-162.66%
Net Profit Margin-163.07%
EBITDA Margin-147.66%
EBIT Margin-159.92%
Analyst Forecast
The average price target for D.Western Therapeutics Institute is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―